EDAP TMS S.A. American Depositary Shares
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FOCL research report →
Range $4 – $15
Price Chart
About the company
EDAP TMS S. A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions.
- CEO
- Ryan Rhodes
- IPO
- 1997
- Employees
- 289
- HQ
- Vaulx-en-Velin, ARA, FR
Get TickerSpark's AI analysis on FOCL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $97.83M
- P/E
- -2.88
- PEG
- 0.06
- P/S
- 1.68
- P/B
- 3.34
- EV/EBITDA
- -3.05
- Div Yield
- 0.00%
- Gross Margin
- 47.59%
- Op Margin
- -46.54%
- Net Margin
- -59.75%
- ROE
- -241.01%
- ROIC
- -38.23%
Latest fiscal year · YoY change
- Revenue
- $70.75M+2.0%
- Gross Profit
- $30.09M+4.8%
- Op Income
- $-25,208,760
- Net Income
- $-29,336,493-42.6%
- EPS
- $-0.78-41.8%
- OCF Growth
- -12.0%
- FCF Growth
- -32.8%
- 52W High
- $6.40
- 52W Low
- $2.11
- 50D MA
- $4.05
- 200D MA
- $4.37
- Beta
- -0.03
- RSI (14)
- 31
- Avg Volume
- 138.76K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
FocalTherics delivered 26% HIFU revenue growth and improved gross margin, but delayed three system sales into Q4 led management to trim full-year guidance.· November 5, 2026
- Q3 HIFU revenue rose to $9.8 million, up 26% year over year, while gross margin improved to 51.4% from 46.6%.
- Seven Focal One capital system sales were completed in the quarter, versus six a year ago, and the global install base reached 192 systems.
- U.S. procedure volumes grew 32% year over year, supported by expanding installed accounts and broader reimbursement momentum.
- Management said three expected system sales slipped out of Q3 because hospital approval processes ran longer and one deal was delayed by bank financing.
- Full-year 2026 revenue guidance was narrowed to $50 million-$52 million from $50 million-$54 million, still implying 34%-39% growth over 2025.
Third-quarter HIFU revenue was $9.8 million, up 26% from $7.8 million in Q3 2025. Gross margin was 51.4% versus 46.6% a year ago, and the company reported net loss of $4.5 million, or $0.10 per share, compared with a net loss of $5.9 million, or $0.16 per share, last year. Operating expenses were $12.8 million versus $10.3 million, and operating loss was $7.8 million versus $6.7 million. Cash and cash equivalents rose to $56.3 million from $21.5 million at the end of Q2, reflecting August equity proceeds. For full-year 2026, management narrowed revenue guidance to $50 million-$52 million from $50 million-$54 million, which they said implies 34%-39% growth over 2025.
Ryan Rhodes said the quarter showed continued execution on the 2026 growth strategy: deeper adoption at leading health systems, broader reimbursement, new clinical indications, and technology innovation. He emphasized that revenue missed expectations only because of deal timing, not demand, and pointed to a strong pipeline and momentum into Q4. He also highlighted progress in salvage therapy coverage, physician education, and early movement in BPH and endometriosis programs.
Ken Mobeck said the quarter benefited from seven system sales and a 24% increase in treatment-driven revenue, with U.S. procedures up 32% year over year. He noted gross margin improved by 482 basis points to 51.4% due mainly to better standard system costs and higher average selling prices for systems and Focalpaks. He also walked through the cost structure, saying operating expenses rose to $12.8 million because of headcount-related compensation and sales/marketing spend, while cash increased to $56.3 million after the August capital raise. On guidance, he said the company narrowed full-year revenue expectations to $50 million-$52 million because of the systems that slipped from Q3.
Analysts focused on why three capital system sales slipped out of Q3 and whether the company’s forecasting has changed. Management said the delays were due to hospital committee processes and, in one case, bank financing timing; they also said one of the three deals had already closed and two purchase orders were signed, with strong active-pipeline momentum into Q4. On growth trends, management said procedure volume growth should remain consistent, though Ken Mobeck cautioned investors to model a moderate ramp because Q4 is the company’s biggest quarter and it takes time to train hospitals and build utilization.
The bull case from the call is that underlying demand appears strong: procedure volumes grew 32%, installed base reached 192 systems, and repeat purchases inside large hospital networks suggest satisfaction with the platform. Reimbursement progress in the U.S. and France, plus expanding clinical indications like salvage therapy, BPH, and endometriosis, give the company multiple paths to sustain growth.
The main risk discussed was execution timing: three expected system sales slipped out of Q3, showing that hospital committee approvals and financing can push revenue into later quarters. Management also acknowledged that utilization ramps take time, implying growth is still dependent on system adoption maturity and training cycles rather than immediate payoff from each placement.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.9%
- Shares Outstanding
- 37.48M
- Float Shares
- 34.07M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Schulz Fran | buy | 10,000 |
| Aug 14, 26 | WILLSEY LANCE | buy | 50,000 |
| Aug 14, 26 | Rhodes Ryan | buy | 21,000 |
| Aug 14, 26 | Shah Sanket | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FOCL coverage
Recent articles, reports, and earnings notes.
No research on FOCL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FOCL report →EDAP TMS S.A. (FOCL) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 10
EDAP TMS S.A. (FOCL) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 8
FocalTherics Q3 Earnings Call Highlights
marketbeat.com · Nov 6
FocalTherics™ Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 5
FocalTherics™ to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 4
FocalTherics™ to Announce Third Quarter 2026 Financial Results on November 5, 2026
globenewswire.com · Oct 22
FocalTherics™ to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 1
Analysts Set FocalTherics (NASDAQ:FOCL) Target Price at $9.00
defenseworld.net · Aug 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.